AffiliationDepartment of Endocrinology, Manchester Royal Infirmary &Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractPituitary tumours are benign but cause significant problems, both because of their compressive effects on brain structures and also because of the syndromes of hormone excess or deficiency that they can cause. Endocrine therapy has become increasingly successful, with the development of dopamine agonists and somatostatin analogues. Recently growth hormone receptor antagonists have been developed by modification of the GH molecule. It is likely that further advances based on our understanding of the biology will dramatically improve the treatment of these tumours.
CitationPituitary tumour therapy: using the biology. 2002, 14 (12):1p following 978 J. Neuroendocrinol.
JournalJournal of Neuroendocrinology
- Recent developments in gene therapy: applications for the treatment of pituitary tumours.
- Authors: Castro MG, Davis JR, Xiong W, Lowenstein PR
- Issue date: 1999 Oct
- The role of somatostatin analogues in the treatment of neuroendocrine tumours.
- Authors: Grozinsky-Glasberg S, Grossman AB, Korbonits M
- Issue date: 2008 May 14
- Pituitary tumours.
- Authors: Davis JR, Farrell WE, Clayton RN
- Issue date: 2001 Mar
- Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
- Authors: Plöckinger U, Quabbe HJ
- Issue date: 2005 May
- The treatment algorithm of acromegaly.
- Authors: Colao A, Pivonello R, Cappabianca P, Vitale G, Lombardi G
- Issue date: 2003